AI
| Followers | 842 |
| Posts | 122790 |
| Boards Moderated | 10 |
| Alias Born | 09/05/2002 |
Friday, January 28, 2011 1:24:01 PM
How does Gilenya affect Copaxone?
According to NVS’ 4Q10 CC, approximately half of Gilenya’s US sales are coming from patients who were not using any MS drugs. Of the other half—i.e. patients who were on another MS drug and switched to Gilenya—25-30% are switching from Copaxone. Thus, each patient start on Gilenya is subtracting 0.125-0.15 patients from the number taking Copaxone.
This graphic comes from NVS’ 4Q10 CC:
Source: http://www.novartis.com/downloads/investors/sales-results/novartis-investor-presentation-fresco-january-27-2011.pdf
According to NVS’ 4Q10 CC, approximately half of Gilenya’s US sales are coming from patients who were not using any MS drugs. Of the other half—i.e. patients who were on another MS drug and switched to Gilenya—25-30% are switching from Copaxone. Thus, each patient start on Gilenya is subtracting 0.125-0.15 patients from the number taking Copaxone.
This graphic comes from NVS’ 4Q10 CC:
Source: http://www.novartis.com/downloads/investors/sales-results/novartis-investor-presentation-fresco-january-27-2011.pdf
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Trade Smarter with Thousands
Leverage decades of market experience shared openly.
